ARWR Stock: Operational Progress and Stock Performance Diverge Despite the stock lagging the markets' performance, Arrowhead ...

Strategic Sarepta partnership and FDA filing position Arrowhead for a transformative leap in RNAi therapeutics ...

RBC Capital analyst Luca Issi maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report) yesterday and set a price target of ...

U.S. stocks on Wednesday slipped, as investors digested a slight acceleration in the Federal Reserve's favorite inflation gauge. Here are some of Wednesday's biggest stock movers: Biggest stock ...

Needham lowered the firm’s price target on Sarepta (SRPT) to $202 from $205 and keeps a Buy rating on the shares. The deal with Arrowhead ...

Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.

($ARWR) and Sarepta Therapeutics Inc. ($SRPT) climbed on Wednesday despite Wall Street trimming price targets after the ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference ...

December S&P 500 E-Mini futures (ESZ24) are up +0.23%, and December Nasdaq 100 E-Mini futures (NQZ24) are up +0.29% this morning as investors assessed the implications of U.S. President-elect Donald ...

After the market close on Tuesday, Iris reported first-quarter Bitcoin BTC/USD mining revenue of $49.6 million. The company ...

Realty Income (NYSE: O) is a wealth-creating machine. Realty Income pays a steadily rising monthly dividend. The REIT has ...

Futures fell slightly with the Fed's favorite inflation gauge on tap. CrowdStrike leads key earnings movers. Amazon and ...